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ing (60 and 70%), and p41i (46 and 57%) and OspC (40 and 
57%) for the IgM class. By the end of the follow-up, only the 
anti-p41i IgM response was significantly decreased to 24%. 
 Conclusions: No correlation was found between IB results 
and treatment-related parameters. Thus, immunoblotting 
does not add to the clinical assessment of EM patients after 
treatment.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Lyme borreliosis (LB) is a multisystem infectious dis-
ease caused by spirochetes of the  Borrelia burgdorferi 
sensu lato ( Bb sl) complex  [1] . Erythema migrans (EM) is 
defined as the hallmark of early LB that is associated with 
 B. afzelii infection in the majority of cases  [2] . It is associ-
ated with unspecific extracutaneous signs and symptoms 
in 30–40% of European patients and up to 70% in North 
American patients  [2] . In untreated cases, spirochetal 
dissemination may lead to other organ manifestations, 
including neurological, musculoskeletal or cardiac disor-
ders  [2] . Adequate antibiotic treatment usually resolves 
EM as well as extracutaneous symptoms within days to 
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 Abstract 
 Objective: We evaluated whether immunoblotting is capa-
ble of substantiating the posttreatment clinical assessment 
of patients with erythema migrans (EM), the hallmark of ear-
ly Lyme borreliosis.  Methods: In 50 patients, seroreactivity 
to different antigens of  Borrelia burgdorferi sensu lato was 
analyzed by a recombinant immunoblot test (IB) in consecu-
tive serum samples from a minimum follow-up period of 1 
year. Antigens in the IgG test were decorin-binding protein 
A, internal fragment of p41 (p41i), outer surface protein C 
(OspC), p39, variable major protein-like sequence expressed 
(VlsE), p58 and p100; those in the IgM test were p41i, OspC 
and p39. Immune responses were correlated with clinical 
and treatment-related parameters.  Results: Positive IB re-
sults were found in 50% before, in 57% directly after therapy 
and in 44% by the end of the follow-up for the IgG class, and 
in 36, 43 and 12% for the IgM class. In acute and convales-
cence phase sera, VlsE was most immunogenic on IgG test-
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weeks, although (intermittent) complaints may some-
times clear slowly  [2, 3] . Subsequent objective neurologi-
cal, cardiac or joint manifestations of LB develop in a mi-
nority of patients  [2, 4] . Patients with true treatment fail-
ure (persistence or recurrence of EM, major sequelae 
and/or survival of  Bb sl) have to be retreated  [5] , whereas 
post-LB syndrome (i.e. long-lasting subjective symptoms, 
such as fatigue, musculoskeletal pain and cognitive dys-
function), which develops in about 10–50% of primarily 
American patients, does not respond to (repeated) anti-
microbial retreatment  [6] .
 So far, no reliable laboratory test is available to sub-
stantiate the clinical assessment of EM patients after an-
tibiotic treatment. Analyses of biopsy samples for the per-
sistence of  Bb sl or  Bb sl-specific DNA in lesional skin by 
cultivation or polymerase chain reaction are very spe-
cific but rather insensitive  [7] . Cultivation is a laborious 
and tedious method, and both procedures are invasive 
and would not detect possible residual borrelial infection 
of other tissues. Culture or polymerase chain reaction 
analyses of blood or urine are less valuable and not estab-
lished for routine diagnosis  [8] . In clinical practice, se-
rum anti- Bb sl antibody analyses would be most conve-
nient, but for enzyme-linked immunosorbent assay (ELI-
SA) testing, it has been shown recently that repeated 
examinations of anti- Bb sl antibodies after antibiotic 
therapy of patients with EM do not provide additional 
information about the efficacy of treatment to the clini-
cian  [9] .
 The immunochemical detection of antibodies against 
a variety of individual proteins of  Bb sl by immunoblot 
(IB) tests provides a superior specificity in the serological 
testing for LB  [10, 11] . Advanced IB tests with additional 
excellent sensitivity rely on recombinant antigens instead 
of whole-cell lysates and the inclusion of antigenic pro-
teins that are expressed primarily in vivo, such as variable 
major protein-like sequence expressed (VlsE)  [12, 13] . In 
Europe, LB is caused by at least 3 different species of  Bb sl, 
 B. afzelii ,  B. garinii and  B. burgdorferi sensu stricto. Thus, 
recombinant IB tests should contain combinations of an-
tigenic proteins from different borrelial species and 
strains, especially if the respective proteins are immuno-
logically heterogenous. The aim of the present study was 
to evaluate by immunoblotting whether changes of anti-
body responses to different borrelial antigens over time 
allow for the assessment of the efficacy of antibiotic ther-
apy, which has not been examined specifically so far. In 
this study a recombinant IB which allows for the combi-
nation of immunodominant proteins from the 3 major 
European  Borrelia species was used  [12] .
 Patients and Methods 
 Patients 
 We carried out a retrospective study of serum anti- Bb sl IgG 
and IgM antibody responses before and after antibiotic therapy 
in 50 patients with EM by IB testing. These 50 patients were se-
lected from a series of 554 consecutive EM cases, seen between 
1998 and 2001 at the Department of Dermatology in Graz, Aus-
tria, based on the following inclusion criteria: (i) EM was diag-
nosed by a dermatologist according to the clinical definition of an 
expanding, sharply demarcated, red to bluish-red erythema of at 
least 5 cm in diameter with or without central clearing  [2, 14, 15] . 
(ii) The patient had been treated with standard oral antibiotic 
therapy  [2, 16] following the clinical diagnosis and had been fol-
lowed for at least 1 year after therapy. (iii) At least 3 serum samples 
from the patient were available for the analysis of anti- Bb sl anti-
bodies, including a sample from directly before therapy and at 
least 2 posttreatment samples. The last sample had to be obtained 
at least 1 year after therapy. (iv) Information on the following 
clinical parameters was available: age, sex, duration of EM before 
therapy, type of EM (solitary vs. multiple), presence of associated 
extracutaneous signs and symptoms, type and duration of antibi-
otic therapy, duration of EM and associated extracutaneous signs 
and symptoms after therapy. Exclusion criteria for our study were: 
(i) reinfection, i.e. history of a previous EM episode or develop-
ment of a second independent EM during the follow-up period; 
(ii) antibiotic treatment before first serum sampling or during the 
follow-up period; (iii) concurrent conditions or therapies with po-
tential influence on the development of anti- Bb sl antibodies (e.g. 
autoimmune disease, malignancy, corticosteroid medication).
 Recombinant Proteins 
 To analyze anti- Bb sl serum IgG and IgM antibodies, an IB test 
was applied that contained a set of recombinant immunodomi-
nant  Bb sl antigens, which were produced by genetic engineering 
as described previously  [12, 17–21] . For most antigens, variants 
from 2–4  Bb sl strains representing the 3 main human pathogenic 
species of  Bb sl were used ( table 1 ). The antigens were: (1) decorin-
binding protein A (DbpA), a lipoprotein that acts as adhesin to 
decorin, a collagen-associated proteoglycan  [22] ; (2) p41i, a 14-
kDa internal fragment of the 41-kDa subunit (p41) of flagellin, a 
polypeptide that makes up the flagella of  Bb sl  [23] – the use of p41i 
instead of whole p41 provides a higher specificity, because it is not 
cross-reactive; (3) outer surface protein C (OspC), the major out-
er surface lipoprotein expressed   by  Bb sl in early   infection  [24, 25] ; 
(4) p39, an immunodominant membrane-associated protein  [19, 
26] ; (5) VlsE, a 35-kDa surface lipoprotein that frequently under-
goes antigenic variation, an important immune evasion mecha-
nism of  Bb sl  [27, 28] ; (6) p58, oligopeptide permease, an immuno-
dominant membrane-associated protein not to be confused with 
the heat shock protein hsp60  [21, 29] ; (7) p83/100, a prominent 
antigen localized to the periplasmic space of  Bb sl with yet unde-
fined function  [30] .
 Immunoblot Testing 
 Of the 50 included patients, a median number of 5 (range 3–8) 
serum samples, which had been obtained directly before and dur-
ing a median follow-up period of 535 days (range 368–1,156 days) 
after therapy and stored at –70 ° C, were available for IB analyses 
of IgG and IgM antibodies to  Bb sl. All samples from each patient 
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were tested together at the same time on serial IB strips from the 
same electrophoresis gel. IB analyses were performed as described 
previously  [12, 19, 21] with different combinations of test antigens 
for the IgG and the IgM class, respectively ( table 1 ). Briefly, IB 
strips were placed into incubation trays with 10 wells each. Strips 
were first incubated with patients’ sera on an orbital shaker over-
night at room temperature in 1: 200 and 1: 100 dilutions for IgG 
and IgM, respectively (dilution buffer: 0.9% sodium chloride, 10 
m M Tris-OH/HCl, pH 7.4, 0.2% Tween 20, 0.4% thimerosal, 1% 
nonfat dried milk). Afterwards, strips were washed for 4  ! 5 min 
(wash buffer: 0.9% sodium chloride, 10 m M Tris-OH/HCl, pH 7.4, 
0.2% Tween 20). Bound antibodies were detected with conjugate 
consisting of horseradish-peroxidase-labeled anti-human immu-
noglobulin (Dako, Glostrup, Denmark) at a dilution of 1: 1,000 for 
IgG and 1: 500 for IgM detection. After 2 h of conjugate incuba-
tion, strips were washed for 4  ! 5 min with wash buffer. Bound 
conjugate was visualized by addition of a chromogenic substrate 
(diaminobenzidine, 10 m M Tris-OH/HCl, pH 7.4, 30% H 2 O 2 ). 
The staining reaction was stopped after 5 min with 1  N H 2 SO 4 . 
For IgM testing, sera were preincubated with rheumatoid factor 
absorbent (Behring, Marburg, Germany) for 30 min at room tem-
perature to eliminate rheumatoid factor activity as well as possi-
ble competitive inhibition by specific IgG antibodies. For valida-
tion, negative and positive control sera were included in each test 
run. IB strips were read independently by one of us (M.G.) and a 
research associate of our laboratory. A band was reported as pos-
itive in case its intensity was at least as strong as the weakly posi-
tive bands of the positive control. For band location, assay strips 
were compared with control strips. Our criteria for a positive IgG 
IB result of a patient were the recognition of at least 2 of the inves-
tigated antigens, and for a positive IgM IB result recognition of at 
least 2 investigated antigens or presence of a single strongly posi-
tive OspC band  [31, 32] .
 ELISA Testing 
 Sera of all patients were also analyzed for anti- Bb sl IgG and 
IgM antibodies by an ELISA test, using purified, native flagella of 
 B. afzelii , strain DK-1, as test antigen (Dako Lyme Borreliosis ELI-
SA Kit; Dako)  [33] . This is a highly immunogenic, phenotypically 
stable flagellum antigen that elicits an early and strong immune 
response  [34] and shows no variation between strains of different 
geographic origins  [33] . All samples of each patient were tested 
together at the same time and on the same well microtitration 
plate in order to avoid intertest variability. 
 Statistics 
 The   2 test was used to assess the following categorical com-
parisons of serological results: number of patients with a positive 
IgG or IgM total IB versus ELISA result before therapy, by the end 
of therapy and by the end of follow-up; and the number of patients 
with a positive IgG or IgM total IB or specific antigen result before 
therapy versus the end of therapy and versus the end of follow-up, 
and between the end of therapy or 1 month after therapy and the 
end of follow-up. Furthermore, a set of clinical parameters (age, 
sex, type, size and duration of EM before therapy, presence of ex-
tracutaneous signs and symptoms, type and duration of therapy, 
duration of EM and extracutaneous symptoms after therapy) 
were compared with pretreatment total or antigen-specific IB re-
sults as well as with the serological courses (decline vs. persistence 
of anti-IgG or -IgM  Bb sl antibodies from before or directly after 
therapy to the end of follow-up) by the appropriate test (  2 test or 
Mann-Whitney rank sum test); p values less than 0.05 were con-
sidered statistically significant, and all tests were two tailed. Sta-
tistical analyses were performed on a personal computer with the 
statistical package Primer of Biostatistics for Windows, version 
4.0 (McGraw-Hill, New York, N.Y., USA).
 Results 
 Clinical Characteristics 
 Fifty patients with EM with a median age of 52.5 years 
(range 12–78 years) were investigated in this study. Thir-
ty patients (60%) were females and 20 (40%) were males. 
The clinical diagnosis was substantiated by either a typi-
cal histopathological picture plus a positive polymerase 
chain reaction for  Bb sl-specific DNA in 48% of the pa-
tients or by histopathology plus cultivation of  Bb sl in 29% 
of the patients. Thus, the clinical and histopathological 
Table 1. Recombinant antigens from different strains of Bbsl used in IB testing of patients with EM
IgG IgM
DbpA p41i OspC p39 VlsE p58 p100 p41i OspC p39
Bbsl strain PKo PKo PKo PKo PKo PKo PKo PKo
PBr
PBi PBi PBi PBi PBi PBi PBi
20047 20047
PKa2 PKa2 PKa2 PKa2 PKa2
DbpA = Decorin-binding protein A; p41i = internal fragment of p41; OspC = outer surface protein C;
VlsE = variable major protein-like sequence expressed. Strain PKo corresponds to the species B. afzelii, strains 
PBr, PBi and 20047 correspond to B. garinii, and strain PKa2 corresponds to B. burgdorferi sensu stricto.
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diagnosis was supported by direct detection of  Bb sl (-spe-
cific DNA) in 77% of all included patients.
 The median duration of EM before therapy was 9.5 
days (range 1–112 days). The median size of the EM le-
sions (largest diameter) was 12 cm (range 5–40 cm). For-
ty-four patients (88%) had a solitary EM lesion, 6 patients 
(12%) had multiple EM lesions. Nineteen patients (38%) 
reported 1 or more extracutaneous signs and symptoms 
of the following distribution: headache (n = 10), elevated 
temperature (n = 7), arthralgias (n = 12), myalgias (n = 6), 
malaise (n = 9) and fatigue (n = 10), whereas 31 patients 
(62%) had no other signs and symptoms. Thirty-six pa-
tients (72%) were treated with tetracyclines (33/36 pa-
tients, 92%, with peroral minocycline and 3/36 patients, 
8%, with doxycycline), 14 patients (28%) received betalac-
tam antibiotics (10/14 patients, 72%, received peroral 
phenoxymethyl penicillin, 3/14 patients, 21%, peroral 
amoxicillin and 1/14 patients, 7%, intravenous ceftriax-
one). Duration of therapy was 2 weeks in 25 patients 
(50%) and 3 weeks in the other half of patients. Overall, 
EM cleared within a median of 14 days (range 1–126 days) 
after initiation of antibiotic therapy. In 29/50 patients 
(58%), it resolved during antibiotic therapy, in 14/50 pa-
tients (28%) within 1 month and in 7/50 patients (14%) 
within 2–5 months after the end of therapy. Extracutane-
ous signs and symptoms disappeared completely within 
a median of 8.5 days (range 1–350 days) after initiation of 
antibiotic therapy in all 19 patients. Resolution was ob-
served in 15/19 patients (79%) during antibiotic therapy, 
in 3/19 patients (16%) within 1 month after the end of 
therapy, and persisted for 12 months in 1 patient (5%). 
Cutaneous or extracutaneous recurrences were not seen 
in any of the patients within the median observation pe-
riod of 535 days (range 368–1,156 days).
 Immunoblot Results 
 The IgG IB test results showed an increase in sensitiv-
ity from before therapy, where half of the patients were 
seroreactive to  Bb sl, to the end of therapy (convalescence 
phase) and further to 1 month after the end of therapy, 
where serological testing yielded positive results in more 
than two thirds of patients ( fig. 1 ). Thereafter, the per-
centage of patients with a positive IgG IB declined to the 
end of the follow-up period, but still almost one half of 
the patients remained seropositive. The decline from the 
percentage of patients with a positive IgG IB between 1 
month after therapy and the end of follow-up was sig-
nificant, but the proportion of positively tested patients 
between before therapy or the convalescence phase did 
not differ significantly from that by the end of follow-up. 
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The IgM IB showed the same development as the IgG IB 
until 1 month after therapy. However, significantly more 
patients were seroreactive before therapy and in the con-
valescence phase compared to the end of follow-up. At all 
time points, sensitivity of IgG IB testing was greater than 
of IgM testing, which was constantly less than 50%. A 
comparison between IB and ELISA testing revealed a sig-
nificantly higher sensitivity for IgG IB testing over ELISA 
testing at all times, whereas for the IgM class, ELISA test-
ing was comparable to the IB with a trend for higher sen-
sitivity.
 Subanalysis of IgG seroreactivity to different proteins 
of  Bb sl revealed that before therapy antibodies were sig-
nificantly more often produced against VlsE than against 
all other proteins (p  ^  0.028;  fig. 2 ). The second most im-
munogenic antigen was p58. However, this protein elic-
ited a significantly greater reactivity only compared to 
OspC (p = 0.021), which had the lowest reactivity with 
IgG antibodies. Analyses of IgG antibody kinetics re-
vealed that for all different  Bb sl proteins, with the excep-
tion of p39, the number of seropositive patients was great-
er in the convalescence phase or 1 month after treatment 
than before therapy. Thereafter, seroreactivity declined 
to the end of follow-up for most antigens, although sig-
nificantly only for VlsE. The continuous decline of sero-
reactivity to p39 from before therapy to the end of follow-
up was not significant (p = 0.056). Thus, a significant 
drop of IgG seroreactivity from before therapy to the end 
of follow-up could not be observed for a single  Bb sl pro-
tein. In IgM analyses, significantly more patients showed 
antibody production to p41i (p  ! 0.001) or OspC (p  ^  
0.003) than to p39 before therapy ( fig. 3 ). Also, IgM reac-
tivity to p41i (p = 0.036) or OspC (p = 0.007) was signifi-
cantly greater than the respective IgG responses before 
therapy, whereas IgM reactivity to p39 (p = 0.193) was 
smaller than IgG reactivity. Changes of IgM antibodies 
to different  Bb sl proteins over time showed an increase in 
the percentage of seropositive patients from before ther-
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apy to the convalescence phase or during the following 
month for all antigens tested. Afterwards, reactivity to 
p41i and OspC dropped significantly to the end of follow-
up, but only slightly for p39. However, comparing the 
number of reactive patients before therapy and the end of 
follow-up, a significant decline was found only for p41i 
(p = 0.036).
 Correlation of Clinical Characteristics with 
Immunoblot Results 
 Patients with a positive IgG IB result before therapy 
had a significantly shorter duration of extracutaneous 
signs and symptoms after therapy than patients with a 
negative pretreatment IgG IB (median, 5.5 vs. 16 days, 
p = 0.040). In patients with IgG reactivity to the VlsE or 
p100 antigen before therapy, duration of EM before ther-
apy was significantly longer than in patients with no re-
activity to these antigens (VlsE: median, 17.5 vs. 8 days, 
p = 0.048; p100: median, 26 vs. 8 days, p = 0.049). Patients 
with a positive IgM IB or IgM reactivity to p41i alone be-
fore therapy were significantly younger than nonreactive 
patients (total IgM: median, 47 vs. 59 years, p = 0.036; 
p41i: median, 47 vs. 58.5 years, p = 0.030). Those with a 
positive IgM IB also had more often multiple EM lesions 
(5/13 vs. 1/31 patients, p = 0.034). Comparison of the 6 
serological constellations with a significant decline of IB 
results from before or directly after therapy to the end of 
follow-up ( fig. 1–3 ) with the clinical variables were sig-
nificant in the following instances: the age of the patients 
was significantly lower in patients with a declining versus 
a persistent IgM IB result from before therapy to the end 
of follow-up (median, 40 vs. 57.5 years, p = 0.006) or de-
clining versus persistent anti-VlsE IgG antibodies from 
directly after therapy to the end of follow-up (median, 46 
vs. 58 years, p = 0.049). Multiple EM lesions, compared to 
solitary lesions, were significantly more often found in 
patients with a significant decline of their IgM IB or of 
anti-p41i antibodies from before therapy to the end of fol-
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low-up (total IgM: 5/9: 1/35, p = 0.006; p41i: 4/8: 2/36, p = 
0.036). None of the treatment-related parameters (type 
and duration of therapy, duration of EM or extracutane-
ous symptoms after therapy) was significantly different 
among patients with declining or persistent IB results.
 Discussion 
 We investigated the long-term IgG and IgM immune 
response to  Bb sl and some different proteins in EM pa-
tients by IB testing. The immunodominant proteins 
throughout the 1-year follow-up period were VlsE in the 
IgG IB and OspC and p41i in the IgM IB. A significant 
decline of the antibody response over time was only found 
against those most antigenic proteins, but decline or per-
sistence of serological responses was not correlated with 
any therapy-related parameter.
 Despite the frequent use of serological control exami-
nations of LB patients following antibiotic therapy, there 
is no larger controlled study that explicitly examined the 
development of immunoreactivity to different  Bb sl pro-
teins in EM patients during an extended posttreatment 
course. In 9 studies  [15, 35–42] which have analyzed anti-
 Bb sl antibodies over time in patients with various mani-
festations of LB by IB tests, a total of 382 subjects with EM 
were included. In these investigations, the follow-up was 
limited to the convalescence phase or subgroups of study 
patients  [36, 38, 40, 41] , serological responses were either 
not discriminated by IgG or IgM antibodies  [36, 41] or 
different specific  Bb sl proteins  [15, 37, 40, 41] or patients 
were not seronaïve  [15] . Of importance, correlations of IB 
results with clinical parameters after therapy have been 
performed in only two American studies with a total of 
61 patients  [35, 42] . The present study is the first to ana-
lyze long-term IgG and IgM seroreactivity to  Bb sl and its 
immunodominant proteins in EM patients before and af-
ter therapy and its correlation with a comprehensive set 
of clinical and therapy-related parameters. The recombi-
nant test system employed in this study combines several 
advantages. As only specific antigens of the 3 major 
pathogenic  Bb sl species present in Europe are included in 
the assay, one test indicates all possible infections and al-
lows for exact identification of the respective antigens on 
the IB strips. In contrast, whole-cell lysate tests which are 
capable of covering infections with different  Bb sl species 
as used in earlier studies  [40, 41] require additional ap-
plication of monoclonal antibodies to exactly identify the 
various antigenic proteins  [43] . In addition, primarily in 
vivo expressed antigens, like VlsE, OspC and DbpA, are 
often not present in sufficient amounts in cultured bor-
reliae  [44] . Very recently described borrelial antigens, 
such as BB0323 and complement regulator-acquiring 
surface protein 3, increase the sensitivity of IB investiga-
tions in neuroborreliosis or Lyme arthritis but not in EM 
 [45] . So far, no data exist about kinetics of serological re-
sponses to these antigens after therapy. Future studies 
have to show whether analyses of these antibodies over 
time could add information to the clinical assessment af-
ter therapy. 
 In general, our IB test was significantly more sensitive 
than the ELISA in detecting IgG  Bb sl antibodies during 
the whole observation period, whereas the IgM ELISA 
was comparable to the IgM IB with a trend for higher 
sensitivity ( fig. 1 ). Differences in sensitivities of the two 
methodologies have been repeatedly described  [36, 38, 
46, 47] and may be due to the time into infection or dif-
ferences in antigen composition and/or concentration be-
tween the assays. In case of IgG, the better reactivity of 
the IB is apparently due to VlsE which is not a test antigen 
in our ELISA. ELISA tests based on C6, a peptide repre-
senting an invariable region of VlsE, reach a sensitivity of 
up to 60%  [48] which is well comparable to the sensitivity 
of our recombinant IB test.
 In IB investigations at baseline, IgG reactivity was ob-
served most frequently to the VlsE antigen followed by 
antibody production to the p58 and the p100 antigen 
( fig. 2 ). For each of the other antigens tested (DbpA, p41i, 
OspC, p39), antibodies were detected in only a quarter of 
patients or less. The same distribution of IgG antibody 
positivity (VlsE  1 p58  1 p100) was observed in the con-
valescence phase as well as 1 month after therapy. IgM 
antibodies at baseline as well as in the convalescence 
phase and 1 month after therapy were most frequently 
observed against the p41i and OspC antigens, whereas 
antibodies against p39 were present in a minority of pa-
tients only ( fig. 3 ). The IgM response to the p41i protein 
preceded the respective IgG response, but a converse IgG/
IgM reactivity was observed for the p39 protein, whereas 
peak seroreactivity to OspC occurred at the same time 
after baseline for the IgG as well as the IgM class ( fig. 2 , 
 3 ). In previous IB studies, the frequencies of individual 
reaction bands at baseline vary widely depending on the 
applied test system (whole-cell lysate vs. recombinant as-
say) and differences of clinical parameters of the investi-
gated patients, particularly disease duration  [32, 38, 39, 
43, 49] . IgG (or IgM) antibodies to p41 before therapy 
were present in 7–94% (19–82%) of patients, to OspC in 
6–77% (41–84%), p39 in 2–85% (0–84%), p58 in 2–54% 
(2–48%), DbpA in 2–53% (2–7%) and p100 in 0–27%. The 
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ranking of seroreactivity to these antigens remained the 
same in the convalescence phase  [38, 39] . The percent-
ages of patients who tested positive for the respective an-
tigens at baseline and in the convalescence phase in our 
study were within the reported ranges. Also, the most 
sensitive antigens on IgM testing in our study (p41i, 
OspC) complied with those from the literature  [24, 32, 38, 
39, 43, 49] . In contrast, the most sensitive antigens on IgG 
testing were different between our study and former in-
vestigations, in which p41 turned out to be most sensitive. 
The difference may be explained by the use of the whole 
flagellin (p41) as test antigen in former studies  [38, 39, 
49] , which is relatively unspecific and cross-reactive, and 
elicits an immune response in a large proportion of pa-
tients  [17, 50] . In contrast, the  Bb sl-specific internal frag-
ment of this protein (p41i) was applied in our study, to 
which only few patients develop antibodies  [32, 49] . IgG 
seroreactivity of EM patients to VlsE, an immunodomi-
nant surface protein of  Bb sl, first introduced in borrelial 
diagnosis in 1999  [51] , has been investigated by IB analy-
sis only once  [32] . As in our study (sensitivity of 60%), in 
this series of 15 untreated EM patients, VlsE was the most 
reactive protein (80%). Several IgG ELISA or chemilumi-
nescence immunoassay-based investigations confirm the 
high sensitivity of antibodies to VlsE or its immunodom-
inant conserved internal region C6 in EM patients before 
therapy (up to 80% of patients)  [52–55] . Thus, IgG anti-
bodies to VlsE and IgM antibodies to OspC and p41 ap-
pear to be the most sensitive markers in IB testing in ear-
ly LB.
 Regarding long-term development of anti- Bb sl anti-
bodies, we found that IgG as well as IgM seroreactivity 
over the 1-year follow-up period displayed a uniform de-
crease following the initial rise during and shortly after 
therapy. This decline was significant only for IgM reac-
tivity, whereas almost half of the patients remained sero-
positive on IgG testing during the whole follow-up peri-
od. The rise of IgG or IgM seroreactivity during therapy 
or the persistence of IgG antibodies in IB tests after 1 year 
of follow-up might be interpreted as a sign of failure of 
antibiotic therapy. However, correlations of serological 
courses with a comprehensive set of clinical parameters 
before and after therapy did not show any relationship 
between serological test results and clinical outcome of 
patients. A comparable peak of positive serological re-
sults by the end of therapy or shortly thereafter followed 
by a fall over the next 12 months, but still with one third 
to half of patients being seropositive, has been described 
in other studies  [38, 39] . There are even descriptions of 
longer persistence  [35, 42] and/or higher percentages  [35] 
of IB positivity in EM patients. In accordance with our 
results, patients with direct postbaseline seroconversion 
or long-term persistence of antibody production had no 
distinct clinical features in the investigations by Aguero-
Rosenfeld et al.  [39] and Feder et al.  [35] . Except for these 
two studies, IB follow-up results were not correlated with 
clinical characteristics elsewhere. Furthermore, it has 
been shown that antibiotic therapy of early LB does not 
necessarily suppress the development of antibodies to 
 Bb sl  [56] . It could rather be speculated that augmented 
presentation of  Bb sl proteins to the host’s immune system 
due to spirochetal disruption by an antimicrobial results 
in an enhanced antibody response. Thus, an increase in 
antibody titers during or shortly after treatment or long-
term serological positivity should not be interpreted as 
evidence for inefficiency of the antibiotic therapy. 
 In line with the literature  [38, 39] and consistent with 
the maximum total IB reactivity during or shortly after 
therapy and its consecutive partial decline in our study, 
IgG as well as IgM reactivity to almost all separately ana-
lyzed proteins of  Bb sl exhibited analogous peaks around 
therapy and a drop of the numbers of reactive patients’ 
sera between 1 and 3 months afterwards. Of importance, 
the long-run decline (pretreatment period to the end of 
the 1-year follow-up) of IgG and IgM seroreactivity to the 
different  Bb sl proteins was not significant with one ex-
ception. More patients recognized the p41i protein frag-
ment before therapy than by the end of follow-up in IgM 
tests. Further significant differences in antibody kinetics 
were only observed when convalescence phase results 
were compared with the end of follow-up, namely for IgM 
anti-OspC and for IgG anti-VlsE antibodies. Three ear-
lier studies with a total of about 100 EM patients  [35, 39, 
42] have analyzed the development of immunoreactivity 
detailed by separate  Bb sl proteins over 1 year or more. In 
general, only a slight decrease in IgM and even less of IgG 
seroreactivity to various distinct proteins, including 
DbpA, OspC, p39, p41, p58 and p100, was observed from 
before therapy to the end of follow-up. Use of the whole 
p41 antigen may be responsible for the persistent anti-fla-
gellin seroreactivity in those studies compared to the sig-
nificant decrease in antibody production to the more spe-
cific truncated p41i protein as used in our study. In ac-
cordance with these results, the few studies investigating 
seroreactivity by IB after treatment in other manifesta-
tions of LB, in particular Lyme arthritis, showed that re-
action bands remained essentially unchanged for even 
many years  [35, 42] .
 For the first time, this study shows by immunoblotting 
persistence of anti-VlsE antibodies for a longer period of 
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time, irrespective of the clinical outcome. ELISA and che-
miluminescence immunoassay studies on the course of 
antibodies to VlsE or its C6 peptide gave contradicting 
results of either a fourfold or greater decline of titers or 
persistence of the antibody response for months or years 
after antibiotic treatment  [55, 57, 58] . Collectively, IgG 
and IgM immunoreactivity to separate  Bb sl proteins as 
analyzed by IB appears to show a uniform course with a 
transient peritherapeutic peak, followed by a mostly in-
significant drop of antibody production resulting in long-
term persistence of seroreactivity.
 So far, only very few studies have specifically addressed 
correlations of clinical characteristics and IB results in 
patients with EM. To investigate whether IB results can 
facilitate clinical decisions, particularly regarding the ef-
ficiency of antibiotic therapy, we compared a comprehen-
sive set of clinical variables with IB results in the present 
study. We found that patients with longer disease dura-
tion before therapy more often produced anti-VlsE and 
-p100 IgG antibodies. In accordance, Aguero-Rosenfeld 
et al.  [36, 39] found a higher percentage of seroreactivity 
to all  Bb sl antigens investigated, including p100, among 
patients with EM of longer disease duration. We and oth-
ers have found the same phenomenon by ELISA testing 
 [9, 39] . In the study by Aguero-Rosenfeld and coworkers, 
patients with longer disease duration also remained pos-
itive for a longer period of time in IgM IB analyses  [39] . 
It thus seems that the probability for a positive pretreat-
ment IB result and persistence of an anti- Bb sl immune 
response is higher in case of a longer pretreatment inter-
action between the host’s immune system and the spiro-
chete. We also found that younger age of patients was 
more frequently associated with a positive pretreatment 
IgM IB result and seroreactivity to the p41i antigen, and 
a more frequent VlsE-specific IgG IB after therapy. In 
ELISA investigations of patients with EM  [9] , elder pa-
tients had a higher probability to remain persistently se-
ronegative. Thus, younger patients seem to develop a 
more vigorous immune response to  Bb sl. Finally, multi-
ple EM lesions were correlated with a positive total IgM 
IB result before therapy. Also other authors have de-
scribed – based on IB and/or ELISA testing – that patients 
with disseminated EM are more prone to produce anti-
bodies to  Bb sl at baseline  [39, 59] . Of importance, neither 
the type of therapy nor outcome-related parameters were 
significantly correlated with any serological constella-
tions in IB testing before or after therapy in the present 
study. Consistent with these results, in another series of 
32 patients with EM persistent or recurrent symptoms 
were not correlated with distinct IB patterns on a follow-
up investigation after a median of 16 months  [35] . Indi-
rect support of these findings comes from a study by Plo-
rer et al. [60] , who did not find differences in IB patterns 
among adequately or inadequately treated patients with 
EM on a single endpoint IB test up to 8 years after the 
disease. Thus, as with ELISA tests  [9, 35] , follow-up IB 
analyses of anti- Bb sl antibodies are not helpful to control 
for the efficiency of antibiotic treatment.
 In conclusion, IgG and IgM immune responses to dif-
ferent antigenic proteins of  Bb sl in patients with EM after 
antibiotic therapy show a uniform temporary peak fol-
lowed by long-term persistence of seroreactivity. No cor-
relation was found between serological courses and type 
or duration of antibiotic therapy or clinical course after 
therapy. Thus, as with ELISA testing, IB analyses in the 
follow-up period of EM do not add to the clinical assess-
ment of treatment response. 
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